Release of the National Strategy for Gene- and Cell-Based Therapies
Join us at the Futurium for the handover of the joint strategy paper with contributions from stakeholders and fields of action.
Abstract
The Federal Ministry of Education and Research (BMBF) has commissioned the Berlin Institute of Health at Charité (BIH) to bring together relevant stakeholders from Germany to develop a national strategy for gene and cell therapies. These stakeholders include actors from science, business, politics and society as well as authorities, foundations and patient organizations. On June 12, 2024 , the jointly developed strategy paper will be presented to the Federal Minister of Education and Research, Bettina Stark-Watzinger, at the Futurium event.
Program
Moderated by: Christina Berndt, science journalist and author
1:00 pm: Open Doors/Admission
2:00 pm: Welcome
Christopher Baum, Chairman of the Board of Directors of the Berlin Institute of Health at Charité (BIH)
2:05 pm: Greetings
Bettina Stark-Watzinger, Federal Minister of Education and Research
2:15 pm: Introduction National Strategy GCT
Christopher Baum, Spokesperson of the National Strategy GCT as well as Chairman of the BIH Board of Directors
2:25 pm: Discussion with the rapporteurs for health research of the current political coalition in the German Parliament
Maximilian Funke-Kaiser, MdB FDP
Laura Kraft, MdB Bündnis 90/Die Grünen
Ruppert Stüwe, MdB SPD
2:40 pm: Official Handover of the National Strategy GCT
2:50 pm: Panel Discussion: What measures are needed to successfully implement the strategy?
Talk with the representatives of the eight fields of action
I) Philipp Beckhove, Scientific Director Leibniz Institute for Immunotherapy Regensburg, Interventional Immunology, University of Regensburg
II) Axel Schambach, Director Institute of Experimental Hematology, Center Internal Medicine, Hannover Medical School and President Deutsche Gesellschaft für Gentherapie e.V. (DG-GT e.V.)
III) Ulrike Protzer, Director Institute of Virology at the School of Medicine and Health, Technical University of Munich and Helmholtz Munich
IV) Isabelle Stöckert, VP, Head Regulatory Affairs EMEA, Bayer AG Pharmaceuticals, Wuppertal
V) Sven Stegemann, Administrative Management Leibniz JointLab “First in Translation" at DWI – Leibniz Institute for Interactive Materials e.V., Aachen
VI) Michael Hudecek, Professorship Cellular Immunotherapy, Medical Clinic and Outpatient Clinic II, University Hospital Würzburg and Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Head of Cellular Immunotherapy Branch, Würzburg
VII) Francis Ayuk, Deputy Director Department of Stem Cell Transplantation, Center for Oncology, University Medical Center Hamburg-Eppendorf, Hamburg and Board Member Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelltherapie (DAG-HSZT) e.V., München
VIII) Tobias Cantz, Head of the Translational Hepatology and Stem Cell Biology Working Group, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology at Hannover Medical School
3:40 pm: Farewell
Christopher Baum, Chairman of the BIH Board of Directors
3:45 pm: Reception
Fields of Action
WG I: Stakeholder Networking and Support
WG II: Training and Development of Skills
WG III: Technology Transfer
WG IV: Standards, Norms and Regulatory Framework
WG V: Increase of Quality and Capacities for GMP Production
WG VI: Research and Development
WG VII: Marketing Authorization and Use in Patient Care
WG VIII: Interaction with Society
Infobox
When
June 12, 2024
at 2:00 pm
Where
Futurium
Alexanderufer 2
D-10117 Berlin
>> Parking facilities are limited. We recommend traveling by public transport.
Registration
Thank you for the great interest in the event.
Unfortunately, registration had to be closed due to limited space.
We are happy to add you to the waiting list. Please contact: gct-event@bih-charite.de
Press
If you are a member of the press and would like to attend the event, please contact: pressestelle-bih@bih-charite.de
